Myriad Genetics (MYGN) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY25 Guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $3.89 -6.04%
Financial Fact:
Earnings per basic share: -0.02
Today's EPS Names:
VIVO, OCCI, ALZN, More
Financial Fact:
Earnings per basic share: -0.02
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.05, $0.06 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $213.1 million versus the consensus estimate of $201.91 million.
GUIDANCE:
Myriad Genetics sees FY2025 EPS of ($0.02)-$0.02, versus the consensus of ($0.01). Myriad Genetics sees FY2025 revenue of $818-828 million, versus the consensus of $811 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Reiterates Buy Rating on Volkswagen AG (VOW:GR) (VWAGY)
- UBS Upgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Buy
- Canaccord Starts L1 Group Ltd (L1G:AU) at Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
